Physician profile
Daniel J Lutz
NPI 1386846251
$3,967.12
in general payments reported to CMS, 2019-2025
17 companies · $909 in 2025
The $909 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $312 · 2021: $299 · 2022: $546 · 2023: $658 · 2024: $841 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,407.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,259.46 | 2019-2025 | Clareon, Rocklatan, Rhopressa |
| Abbvie INC. | $658.78 | 2022-2025 | |
| Allergan, INC. | $231.24 | 2019-2021 | |
| Glaukos Corporation | $225.86 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $115.40 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $114.16 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $67.37 | 2022-2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $60.88 | 2019 | |
| Ocular Therapeutix, INC. | $37.96 | 2024-2025 | Dextenza |
| New World Medical,INC. | $33.96 | 2023-2025 | Via360, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Bausch & Lomb Americas INC. | $32.84 | 2023-2025 | Vyzulta, Xiidra, Miebo |
| Sun Pharmaceutical Industries INC. | $27.33 | 2019 | |
| Astellas Pharma US INC | $27.30 | 2024 | Izervay |
| Sight Sciences, INC. | $21.03 | 2022 | |
| Genentech USA, INC. | $18.35 | 2025 | Vabysmo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $17.74 | 2022 | |
| Aerie Pharmaceuticals, INC. | $17.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lutz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.